Search the Newsreel

Form 8K Lexeo Therapeutics Inc For: 12 August By Investing.com

The article reports that Lexeo Therapeutics Inc. filed a Form 8K on August 12. It briefly mentions the company name and filing date, without providing further details on the content of the filing. The article is very short and seems to act as a …

Lexeo Therapeutics, Inc. 2Q 2026: Net loss $25.9M, EPS $(0.30) — 10-Q Summary

Lexeo Therapeutics, Inc. reported a net loss of $25.9 million and an EPS of $(0.30) for the second quarter of 2026, remaining pre-revenue. The company highlighted clinical progress for LX2006 and LX2020, including the initiation of a pivotal trial for LX2006 and RMAT designation …

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics announced its second quarter 2026 financial results and operational highlights, focusing on advancements in its gene therapy pipeline. Key achievements include the initiation of the pivotal SUNRISE-FA 2 trial for LX2006 in Friedreich ataxia cardiomyopathy and the FDA's RMAT designation for LX2020 …

LXEO: Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway

Lexeo Therapeutics (LXEO) is focused on gene therapies for rare cardiac diseases, with a pipeline that includes two clinical-stage and two preclinical programs. Its lead candidates, LX2006 and LX2020, are showing promising efficacy and safety data, with key milestones anticipated. The company reports strong …

Lexeo Therapeutics advances gene therapy and gains RMAT status

AQR Capital discloses 11.0M-share Exelixis (EXEL) position at 4.39% ownership

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have disclosed a beneficial ownership of 11,023,943 shares of Exelixis, Inc. common stock, representing 4.39% of the class. The filing indicates shared voting power over 10,935,221 shares and shared dispositive power over all 11,023,943 …

Lexeo Therapeutics (LXEO) narrows loss and ends H1 2026 with $234M cash

Expand Energy Corporation (NASDAQ:EXE) Receives Consensus Rating of "Moderate Buy" from Analysts

Expand Energy Corporation (NASDAQ:EXE) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $129. The company recently reported adjusted quarterly earnings of $1.33 per share, surpassing estimates, though revenue fell slightly below forecasts. Expand Energy also declared …

We Think Crexendo's (NASDAQ:CXDO) Profit Is Only A Baseline For What They Can Achieve

Crexendo, Inc. (NASDAQ:CXDO) recently posted solid earnings, but the market appears to be overly pessimistic. Analysis shows that the company's statutory earnings are likely conservative due to a negative accrual ratio and the impact of unusual items. However, shareholder dilution from new share issuance …

Benchmark Adjusts Price Target on Expand Energy to $109 From $124, Maintains Buy Rating

Benchmark has revised its price target for Expand Energy (EXE) to $109 from $124, while reiterating a Buy rating on the stock. This adjustment comes despite recent varied analyst adjustments to Expand Energy's price target, with some increasing and others decreasing their targets. Expand …

Extendicare Inc. Stock Faces Renewed Pressure as Investor Caution Builds

Lexeo Therapeutics (LXEO) Earnings Date and Reports 2026

Dimensional Fund Advisors LP Increases Holdings in Lexeo Therapeutics, Inc. $LXEO

Dimensional Fund Advisors LP significantly increased its stake in Lexeo Therapeutics, Inc. during the first quarter, now owning 1.41% of the company's shares. Despite this institutional interest, Lexeo insiders, including the CEO, recently sold shares primarily to cover tax obligations on vested equity awards. …

Crexendo Inc (CXDO) (Q2 2026) Earnings Call Highlights: Revenue Surges 49% as Platform Wins ...

Crexendo reported strong Q2 2026 results with a 49% revenue increase to $24.6 million, driven by the ESI acquisition and growth in telecom services. The company achieved GAAP net income of $1.1 million and a substantial increase in new platform customers, securing 11 new …

Exelixis (EXEL) Earnings Strength Meets Lower Guidance As Valuation Comes Back Into View

Crexendo (CXDO) Q2 2026 Earnings Call Transcript

Crexendo reported strong Q2 2026 results with a 49% revenue increase to $24.6 million, driven by the ESI acquisition and growth in telecom services. The company achieved GAAP net income of $1.1 million and a substantial increase in new platform customers, securing 11 new …

Crexendo (CXDO) is an Incredible Growth Stock: 3 Reasons Why

Crexendo (CXDO) is identified as an incredible growth stock by Zacks' proprietary system, earning a favorable Growth Score and a top Zacks Rank. The company shows strong prospects with an expected EPS growth of 25% this year, crushing the industry average, and an impressive …

EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis

SueWallSt is investigating potential securities claims against Exelixis (NASDAQ: EXEL) following a reduction and narrowing of its full-year 2026 revenue guidance. The company's shares declined after it cited a slower-than-expected ramp in its neuroendocrine-tumor business, contradicting earlier reiterations of its financial outlook. Shareholders who …

Crexendo’s cloud communications platform reaches 8M users By Investing.com

Crexendo, Inc. announced its cloud communications platform now supports over 8 million users worldwide, adding approximately one million users in eight months. The platform has grown over 370% since Crexendo acquired NetSapiens in June 2021. The company's platform includes CAIRO, an AI receptionist and …

CXDO Looks 8.2% Undervalued on GF Value™

Crexendo Inc (NASDAQ: CXDO) is currently deemed 8.2% undervalued by GuruFocus' GF Value™, with a current price of $6.30 against an intrinsic value of $6.86. The company recently announced its AI-driven UCaaS platform surpassed 8 million global users, reflecting significant growth. While insider selling …

Exelon Adds Public Grid and Buckstop to 2c2i Portfolio, Advancing Affordable and Sustainable Energy Solutions

CHICAGO, August 11, 2026--(BUSINESS WIRE)--The Exelon Foundation has added two new companies to its Climate Change Investment Initiative (2c2i) portfolio: Public Grid and Buckstop. The investments reflect Exelon's commitment to supporting solutions that improve affordability, make better use of resources and contribute to a …

Exelon Backs a Platform Connecting Residents to Energy-Saving Programs

The Exelon Foundation has invested in Public Grid and Buckstop through its Climate Change Investment Initiative (2c2i). Public Grid connects residents to energy-saving programs through multifamily housing, aiming to reduce costs and promote efficient energy use. Buckstop focuses on recovering value from existing materials …

Crexendo Cloud Platform Adds About 1M Users Worldwide in 8 Months

Crexendo (NASDAQ: CXDO) announced that its AI-enhanced UCaaS cloud communications platform now supports over 8 million users worldwide, an increase of approximately one million users since late 2025. The platform's user base has grown over 370% since the June 2021 acquisition of NetSapiens. The …

Expand Energy (EXE) Could Be 21% Undervalued On Mixed Earnings And Steady Shareholder Returns

Exelon's MidAtlantic Utilities Face Challenges to Serve Data Center Growth

Exelon's MidAtlantic utilities are facing challenges in meeting the increasing demand for power from data centers, an issue that is causing investor concern. This report from Morningstar analyst Andrew Bischof highlights the difficulties for the pure-play electric and gas transmission and distribution utility. Previous …

Is It Too Late to Buy Expand Energy Corp (EXE) After 5.1% Rally? GF Value Says Undervalued

Expand Energy Corp (EXE) shares recently rallied by 5.1% but are still considered undervalued by 18.4% according to GuruFocus' GF Value, which estimates its fair value at $119.58. The company has an average GF Score of 57/100, with strong financial strength but concerning growth. …

Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)

Levi & Korsinsky, LLP has announced an investigation into Exelixis (EXEL) after the company reiterated its full-year 2026 financial guidance on May 5, 2026, only to lower and narrow its revenue outlook weeks later, causing a stock decline. The investigation focuses on whether Exelixis …

EXELIXIS, INC. SEC Filing (Aug 10, 2026)

This article reports on an SEC Form 144 filing by Exelixis, Inc. (EXEL) on August 10, 2026. The filing indicates a proposed sale of 9,812 shares of common stock with an aggregate market value of $526,496.22, acquired on May 29, 2026, through a restricted …

Crexendo posts investor presentation to website under Regulation FD

Crexendo (CXDO) announced it has posted an investor presentation on its investor relations website, www.crexendo.com

Expand Energy Corp (EXE:UN): Stock Price, Quote and News

The article provides the stock price, quote, and news for Expand Energy Corp (EXE:UN). It appears to be a stub or a placeholder page from BNN Bloomberg, indicating where information for this company would typically be found. No specific financial data or news content …

Expand Energy Corporation (CS1.DE) Analyst insights, Price targets and Recommendations

This article provides a brief overview of Expand Energy Corporation (CS1.DE), including its current stock price and recent analyst ratings. The company recently announced a cash dividend and has received consistent "Buy" and "Overweight" ratings from several financial institutions like UBS, Truist Securities, Citigroup, …

Exelon Corp. stock underperforms Monday when compared to competitors

Exelon Corp. (EXC) stock fell 2.43% to $44.50 on Monday, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average also decline. The company's shares closed 12.14% below their 52-week high of $50.65.

Extendicare Inc. (TSX:EXE) Stock Declines 5.12% as Healthcare Cost Pressures and Investor Caution Weigh on Outlook

Form 8K Crexendo For: 10 August By Investing.com

This article reports on a Form 8K filing by Crexendo for August 10th. The brief piece includes the company's stock symbol CXDO and its current performance of +2.06%. It also shows general market data for various indices, commodities, bonds, and shares.

Interested In Expand Energy's (NASDAQ:EXE) Upcoming US$0.575 Dividend? You Have Four Days Left

Expand Energy Corporation (NASDAQ:EXE) is set to go ex-dividend in four days, with a US$0.575 per share dividend to be paid on September 3rd. While the company's dividend is well-covered by both earnings (27% payout ratio) and free cash flow (31% payout ratio), its …

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has received an average "Buy" rating from nine brokerage firms, with an average 12-month price target of $18.75. Despite insider sales totaling $280,089 over the past three months, institutional investors collectively own 60.67% of the company. The company's stock currently …